Cargando…
In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [(18)F]FDG and [(64)Cu]Cu-LLP2A PET
BACKGROUND: Multiple myeloma (MM) is a disease of cancerous plasma cells in the bone marrow. Imaging-based timely determination of therapeutic response is critical for improving outcomes in MM patients. Very late antigen-4 (VLA4, CD49d/CD29) is overexpressed in MM cells. Here, we evaluated [(18)F]FD...
Autores principales: | Ghai, Anchal, Fettig, Nikki, Fontana, Francesca, DiPersio, John, Rettig, Mike, Neal, Julie O., Achilefu, Samuel, Shoghi, Kooresh I., Shokeen, Monica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481408/ https://www.ncbi.nlm.nih.gov/pubmed/34586539 http://dx.doi.org/10.1186/s13550-021-00840-4 |
Ejemplares similares
-
First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging
por: Laforest, Richard, et al.
Publicado: (2023) -
Integrated (64)Cu therapy for the peritoneal dissemination of gastrointestinal cancer
por: Kurihara, Hiroaki
Publicado: (2018) -
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival
por: Hathi, Deep, et al.
Publicado: (2022) -
(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012) -
Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)